肝动脉化疗栓塞联合阿帕替尼治疗中晚期肝细胞癌的疗效分析  

Efficacy of Hepatic Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

作　　者：陈健[1] 姜成毅 刘璐 李佰萍 孙志强[2] CHEN Jian;JIANG Chengyi;LIU Lu;LI Baiping;SUN Zhiqiang(Department of Interventional,Jilin Provincial Cancer Hospital,Changchun,Jilin Province,130000 China;Department of General Surgery,Jilin Provincial Cancer Hospital,Changchun,Jilin Province,130000 China;DepartmentⅡof Internal Medicine,Jilin Provincial Cancer Hospital,Changchun,Jilin Province,130000 China)

机构地区：[1]吉林省肿瘤医院介入科,吉林长春130000 [2]吉林省肿瘤医院综合外科,吉林长春130000 [3]吉林省肿瘤医院内二科,吉林长春130000

出　　处：《中外医疗》2023年第16期27-30,共4页China & Foreign Medical Treatment

基　　金：吉林省卫生健康科技能力提升项目(2021LC132);吉林省科技发展计划项目(20190303168 S)。

摘　　要：目的探讨肝动脉化疗栓塞联合阿帕替尼治疗中晚期肝细胞癌的临床效果。方法回顾性分析2020年9月—2021年10月期间在吉林省肿瘤医院治疗的114例肝细胞癌患者的临床资料,按照治疗方法分为对照组与观察组,每组57例。对照组患者单独应用肝动脉化疗栓塞方案,观察组患者则采取肝动脉化疗栓塞联合阿帕替尼方案,对比分析两组治疗效果、人热休克蛋白90α(Hsp90α)和甲胎蛋白(AFP)水平变化。结果观察组治疗有效率为85.96%,高于对照组的54.38%,差异有统计学意义(χ^(2)=13.579,P<0.05)。治疗前,两组Hsp90α及AFP水平比较,差异无统计学意义(t=0.145、0.494,P=0.884、0.621);治疗后,两组Hsp90α和AFP水平均下降,且观察组低于对照组,差异有统计学意义(t=15.076、13.910,P<0.05)。结论肝动脉化疗栓塞联合阿帕替尼治疗中晚期肝细胞癌具有良好的干预效果,且能改善Hsp90α和AFP水平。Objective To investigate the clinical effect of hepatic arterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma.Methods Retrospective analysis of clinical data of 114 patients with hepatocellular carcinoma treated at Jilin Provincial Cancer Hospital from September 2020 to October 2021,they were divided into a control group and an observation group according to treatment methods,with 57 cases in each group.The patients in the control group were treated with hepatic artery chemoembolization alone,while the patients in the observation group were treated with hepatic artery chemoembolization combined with Apatinib.The therapeutic effects,human heat shock protein 90α(Hsp90α)and alpha fetoprotein(AFP)levels in the two groups were compared and analyzed.Results The effective rate of treatment in the observation group was 85.96%,higher than 54.38%in the control group,and the difference was statistically significant(χ^(2)=13.579,P<0.05).Before treatment,there was no statistically significant difference in Hsp90αand AFP levels between the two groups(t=0.145,0.494,P=0.884,0.621);after treatment,the levels of Hsp90αand AFP in two groups were decreased,and the observation group was lower than the control group,and the difference was statistically significant(t=15.076,13.910,P<0.05).Conclusion Hepatic artery chemoembolization combined with Apatinib in the treatment of advanced hepatocellular carcinoma has a good intervention effect,and can improve the level of Hsp90αand AFP.

关 键 词：肝动脉化疗栓塞 阿帕替尼 中晚期肝细胞癌 

分 类 号：R4[医药卫生—临床医学]